GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bio Plus Co 099430.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

2,980

+1.53%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bio Plus Co

Its shares trade on KOSDAQ under the ticker 099430.KQ. It has been listed since 27 September 2021. In the fiscal year to 31 December 2025, it reported revenue of ₩90.90bn and net income of ₩15.00bn. At that date it held total assets of ₩285.04bn and shareholders' equity of ₩174.84bn.

BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
27 Sept 2021

Leadership

Pay as last reported

  • Mr. Hyun Kyu JungChairman of the Board, Chief Executive Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Bio Plus Co Ltd manufactures diverse dermal fillers for the Health Care sector.
  • The company produces hyaluronic acid fillers to improve facial wrinkles temporarily.
  • Bio Plus Co Ltd supplies anti-adhesion agents for surgical areas effectively.

Weaknesses

  • The company is headquartered in Seongnam, which limits local market reach.
  • Bio Plus Co Ltd went public on 27 September 2021 recently.
  • The firm operates in the Health Care sector with limited product diversity.

Opportunities

  • Bio Plus Co Ltd can expand biomaterials for joint tissue repair sales.
  • The company may increase production of anti-adhesion agents for surgical markets.
  • Bio Plus Co Ltd can supply more hyaluronic acid fillers globally.

Threats

  • Bio Plus Co Ltd faces competition in the Health Care sector.
  • The company relies on the Seongnam headquarters for operational management.
  • Bio Plus Co Ltd must maintain quality for dermal fillers strictly.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.